BUDGET IMPACT ANALYSIS OF NILOTINIB AS FIRST LINE TREATMENT OF NEWLY DIAGNOSED PATIENTS WITH CHRONIC MYELOID LEUKEMIA (CML) WITH HIGH RISK SOKAL SCORE IN THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM

被引：0
|
作者：
Kim, H. S. J. [1 ]
Buehler, A. [1 ]
Matsuo, A. L. [1 ]
机构：
[1] Novartis Biociencias SA, Sao Paulo, SP, Brazil
来源：
VALUE IN HEALTH | 2019年 / 22卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN139
引用
收藏
页码：S462 / S462
页数：1
相关论文
共 50 条
  • [1] BUDGET IMPACT ANALYSIS OF TREATMENT-FREE REMISSION (TFR) OF NILOTINIB THERAPY IN CHRONIC MYELOID LEUKEMIA (CML) PATIENTS IN THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM (BPHS)
    Kim, H.
    Fahham, L.
    Hazarbassanov, N. G. T. D. Q.
    Vivona, D.
    VALUE IN HEALTH, 2020, 23 : S440 - S440
  • [2] BUDGET IMPACT ANALYSIS OR PHARMACOLOGICAL THERAPY OF CHRONIC MYELOID LEUKEMIA (CML) WITH NILOTINIB AS THE SECOND-LINE TREATMENT IN RUSSIAN FEDERATION
    Serpik, V. G.
    Yagudina, R.
    VALUE IN HEALTH, 2015, 18 (07) : A442 - A442
  • [3] Sokal Risk Score Is Superior to Hasford and EUTOS in Determining Survival Outcomes for Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Patients
    Jiang, Brian Gabriel
    Kim, Dong-Wook
    Shih, Lee-Yung
    Chuah, Charles
    Than, Hein
    Kuo, Ming-Chung
    Li, HuiHua
    Allen, John Carson, Jr.
    See, Lionel K. Y.
    Yap, Bernard K. C.
    Goh, Yeow-Tee
    BLOOD, 2015, 126 (23)
  • [4] BUDGET IMPACT ANALYSIS FOR NILOTINIB USE IN THE TREATMENT OF CHRONIC MYELOID LEUKEMIA IN COLOMBIA
    Romero, M.
    Acero, G.
    Marrugo, R.
    VALUE IN HEALTH, 2014, 17 (03) : A75 - A75
  • [5] An analysis of the kinetics of molecular response during the first trimester of treatment with nilotinib in newly diagnosed chronic myeloid leukemia patients in chronic phase
    Luis Steegmann, Juan
    Colomer, Dolors
    Gomez-Casares, Maria-Teresa
    Garcia-Gutierrez, Valentin
    Orti, Guillermo
    Ramirez-Payer, Angel
    Olavarria, Eduardo
    Vall-llovera, Ferran
    Giraldo, Pilar
    Conde, Eulogio
    Vallansot, Rolando
    Luis Lopez-Lorenzo, Jose
    Palomera, Luis
    Alvarez-Larran, Alberto
    Conesa, Venancio
    Bautista, Guiomar
    Casas, Laura
    Giles, Frank
    Hochhaus, Andreas
    Felipe Casado-Montero, Luis
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2017, 143 (10) : 2059 - 2066
  • [6] An analysis of the kinetics of molecular response during the first trimester of treatment with nilotinib in newly diagnosed chronic myeloid leukemia patients in chronic phase
    Juan Luis Steegmann
    Dolors Colomer
    Maria-Teresa Gómez-Casares
    Valentín García-Gutiérrez
    Guillermo Ortí
    Angel Ramírez-Payer
    Eduardo Olavarria
    Ferrán Vall-llovera
    Pilar Giraldo
    Eulogio Conde
    Rolando Vallansot
    Jose Luis López-Lorenzo
    Luis Palomera
    Alberto Álvarez-Larrán
    Venancio Conesa
    Guiomar Bautista
    Laura Casas
    Frank Giles
    Andreas Hochhaus
    Luis Felipe Casado-Montero
    Journal of Cancer Research and Clinical Oncology, 2017, 143 : 2059 - 2066
  • [7] COST-UTILITY ANALYSIS OF NILOTINIB COMPARED TO IMATINIB FOR NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA (CML) IN CHRONIC PHASE
    Inocencio, T. J.
    Seetasith, A.
    Newland, A.
    Bose, P.
    Holdford, D.
    VALUE IN HEALTH, 2012, 15 (04) : A223 - A223
  • [8] Treatment patterns and healthcare costs among newly-diagnosed patients with chronic myeloid leukemia receiving dasatinib or nilotinib as first-line therapy in the United States
    Latremouille-Viau, Dominick
    Guerin, Annie
    Nitulescu, Roy
    Gagnon, Patrick S.
    Joseph, George J.
    Chen, Lei
    JOURNAL OF MEDICAL ECONOMICS, 2017, 20 (01) : 63 - 71
  • [9] Treatment Patterns and Healthcare Costs in Newly Diagnosed Patients with Chronic Myeloid Leukemia Receiving Dasatinib or Nilotinib As First-Line Therapy in the United States: A Retrospective Claims Database Analysis
    Chen, Lei
    Latremouille-Viau, Dominick
    Guerin, Annie
    Nitulescu, Roy
    Gagnon-Sanschagrin, Patrick
    BLOOD, 2015, 126 (23)
  • [10] Correction to: An analysis of the kinetics of molecular response during the first trimester of treatment with nilotinib in newly diagnosed chronic myeloid leukemia patients in chronic phase
    Juan Luis Steegmann
    Dolors Colomer
    Maria-Teresa Gómez-Casares
    Valentín García-Gutiérrez
    Guillermo Ortí
    Angel Ramírez-Payer
    Eduardo Olavarria
    Ferrán Vall-llovera
    Pilar Giraldo
    Eulogio Conde
    Rolando Vallansot
    Jose Luis López-Lorenzo
    Luis Palomera
    Alberto Álvarez-Larrán
    Venancio Conesa
    Guiomar Bautista
    Laura Casas
    Frank Giles
    Andreas Hochhaus
    Luis Felipe Casado-Montero
    Journal of Cancer Research and Clinical Oncology, 2018, 144 : 187 - 188
12345